Summary In the Nordic Society for Paediatric Haematology and Oncology paediatric study
acute myeloid leukaemia (AML) 93, event‐free survival was 50% and overall survival was …

Abstract Between May 1988 and March 1995, 359 children with acute myeloid leukaemia
(AML) were treated in the MRC AML 10 trial. Three risk groups were identified based on …

Summary Given that 30–40% of children with acute myeloid leukaemia (AML) relapse after
primary therapy it is important to define prognostic factors and identify optimal therapy. From …

The outcomes of children with relapsed acute myeloid leukemia (AML) are known to be
poor, but remain obscure. We retrospectively analyzed 71 patients who had relapsed …

Simple Summary Acute myeloid leukemia in children remains a difficult disease to cure
despite intensive therapies that push the limits of tolerability. Though the intent of initial …

The prognosis of paediatric acute myeloid leukaemia (AML) has improved significantly over
the recent decades, but still about one‐third of patients relapse. These patients have a …

Background Current event‐free survival (EFS) rates for children with newly diagnosed acute
myeloid leukemia (AML) approach 50–60%. We hypothesize that further improvements in …

Although treatment of childhood acute myelogenous leukemia (AML) has substantially
improved in the last 15 years, in nearly half of the patients disease recurs. The aim of this …

We reviewed 70 consecutive children with AML who received hematopoietic stem cell
transplantation (HSCT) in our institution between 1994 and 2005. Forty-seven children were …

Paediatric patients with acute myeloid leukaemia (AML) who fail induction due to primary
resistance to chemotherapy account for a significant proportion of cases and have a …